Cargando…

Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells

Although CD138 expression is a hallmark of plasma cells and myeloma cells, reduced CD138 expression is occasionally found. However, the mechanisms underlying CD138 downregulation in myeloma cells remain unclear. Previous reports suggest that the bone marrow microenvironment may contribute to CD138 d...

Descripción completa

Detalles Bibliográficos
Autores principales:	KAWANO, YAWARA, KIKUKAWA, YOSHITAKA, FUJIWARA, SHIHO, WADA, NAOKO, OKUNO, YUTAKA, MITSUYA, HIROAKI, HATA, HIROYUKI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834117/ https://www.ncbi.nlm.nih.gov/pubmed/24126540 http://dx.doi.org/10.3892/ijo.2013.2134

Ejemplares similares

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
por: KAWANO, YAWARA, et al.
Publicado: (2012)

Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1
por: Fujiwara, Shiho, et al.
Publicado: (2015)

Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells
por: WADA, NAOKO, et al.
Publicado: (2014)

Bufalin induces DNA damage response under hypoxic condition in myeloma cells
por: Fujii, Eri, et al.
Publicado: (2018)

PDK1 inhibition is a novel therapeutic target in multiple myeloma
por: Fujiwara, S, et al.
Publicado: (2013)

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines
por: Paíno, Teresa, et al.
Publicado: (2014)

Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib‐sensitive and ‐resistant multiple myeloma cells
por: Nishimura, Nao, et al.
Publicado: (2019)

Pancytopenia and Myelodysplastic Changes in Aceruloplasminemia: A Case with a Novel Pathogenic Variant in the Ceruloplasmin Gene
por: Yamamura, Ayako, et al.
Publicado: (2018)

Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma
por: Soloveva, Maiia, et al.
Publicado: (2023)

Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma()
por: Krishnan, Sabna Rajeev, et al.
Publicado: (2016)

Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout
por: Jacak, Jaroslaw, et al.
Publicado: (2013)

Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells
por: Kishimoto, Renata Kiyomi, et al.
Publicado: (2016)

Comment on: “Validation of interphase fluorescence in situ hybridization (iFISH) of CD138 positive cells in multiple myeloma”()
por: Zalcberg Renault, Ilana
Publicado: (2016)

A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients
por: Bae, Jooeun, et al.
Publicado: (2014)

Cardiovascular Involvement of a CD138-Negative Anaplastic Myeloma: A Diagnostic Dilemma
por: Choudhuri, Jui, et al.
Publicado: (2023)

Rare concurrent indolent B-cell lymphoma and plasmablastic transformation of myeloma
por: Saburi, Masuho, et al.
Publicado: (2018)

Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells
por: Jeong, Tae-Dong, et al.
Publicado: (2012)

Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study
por: Dass, Jasmita, et al.
Publicado: (2019)

Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device
por: Qasaimeh, Mohammad A., et al.
Publicado: (2017)

An IL‐27/Stat3 axis induces expression of programmed cell death 1 ligands (PD‐L1/2) on infiltrating macrophages in lymphoma
por: Horlad, Hasita, et al.
Publicado: (2016)

In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma
por: Omstead, David T., et al.
Publicado: (2020)

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
por: Sun, Chuang, et al.
Publicado: (2019)

An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells
por: Nakayama, Shoko, et al.
Publicado: (2012)

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility
por: Misiewicz-Krzeminska, Irena, et al.
Publicado: (2018)

CD138(-) multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient
por: Wu, Dong, et al.
Publicado: (2020)

Base-to-apex gradient pattern of cardiac impairment identified on myocardial T1 mapping in cardiac amyloidosis
por: Oda, Seitaro, et al.
Publicado: (2018)

Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma
por: Cengiz, Arzu, et al.
Publicado: (2018)

Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?
por: Lee, Je-Jung
Publicado: (2010)

MicroRNA-138 Regulates Hypoxia-Induced Endothelial Cell Dysfunction By Targeting S100A1
por: Sen, Anagha, et al.
Publicado: (2013)

High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma
por: Ibata, Soushi, et al.
Publicado: (2018)

Junctional adhesion molecule C expression specifies a CD138(low/neg) multiple myeloma cell population in mice and humans
por: Brandl, Andreas, et al.
Publicado: (2022)

PB2077: COMPARISON OF PLASMA CELL PERCENTAGE BY BONE MARROW ASPIRATE MORPHOLOGY AND CD138-STAINED BONE MARROW BIOPSY IN SMOLDERING MYELOMA TO PREDICT TRANSFORMATION TO SYMPTOMATIC MYELOMA
por: Cashman, Helen, et al.
Publicado: (2023)

Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins
por: Jung, O, et al.
Publicado: (2016)

Correction: MicroRNA-138 Regulates Hypoxia-Induced Endothelial Cell Dysfunction By Targeting S100A1
por: Sen, Anagha, et al.
Publicado: (2013)

Correction: MicroRNA-138 Regulates Hypoxia-Induced Endothelial Cell Dysfunction By Targeting S100A1
por: Sen, Anagha, et al.
Publicado: (2014)

Paclitaxel-Fe(3)O(4) nanoparticles inhibit growth of CD138(−) CD34(−) tumor stem-like cells in multiple myeloma-bearing mice
por: Yang, Cuiping, et al.
Publicado: (2013)

Immature T cell neoplasms in three young cattle
por: YOKOTA, Rie, et al.
Publicado: (2015)

Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
por: Fujimoto, Yuki, et al.
Publicado: (2021)

Plasma cell myeloma with immature plasma cells in the skin arising within the areas of chronic stasis dermatitis
por: Karri, Padmavathi, et al.
Publicado: (2020)

Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma
por: Ikeda, Sho, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0vie8bu6jruqjoqt5jq6ipl9uh